Right Temporal Variant Frontotemporal Dementia Presenting With Prosopagnosia: Insights From 18 F-FDG PET and MRI.

Clin Nucl MedMar 19, 2026 (epub)
Case ReportNeurology

Muhammet Halil Baltacioglu, Pelin Sahin Oguz, Mehmet Sabri Erdol

✦ AI-curated · Sources linked

Case in brief

A 62-year-old man developed progressive difficulty recognizing people, accompanied by memory impairment. T2-weighted MRI showed atrophy of the right anterior temporal region. 18F-FDG PET demonstrated marked hypometabolism in the right temporal lobe, with additional involvement of the right frontal and anterior cingulate cortices; quantitative SPM Z-score analysis supported these findings. The combined structural and metabolic pattern was consistent with right temporal variant frontotemporal dementia, which affects networks involved in person recognition.

What made this case unusual

The case provides a multimodal depiction of right temporal variant frontotemporal dementia, including detailed 18F-FDG PET findings alongside MRI; the authors note that such PET characterization remains scarce.

Diagnostic / clinical pearl

Progressive prosopagnosia with right anterior temporal atrophy and corresponding right temporal hypometabolism can point to right temporal variant frontotemporal dementia.

Source

PubMed · PMID 41911262

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.